This session will be a practical basic science review on the immunology of AD and the role of the JAK/TEC pathway.
- Review the immune mechanisms involved in the pathogenesis of AD
- Describe emerging targets (such as JAK and TEC kinase related pathways) for AD and how their modulation affects inflammation
- Differentiate the immunological pathways of AD and the JAK/TEC inhibition pathways
Disclosure of Conflicts of Interest
Your CE Source ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, Your CE Source identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Your CE Source to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Your CE Source is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Faculty||Reported Financial Relationship|
|James Song, MD||
Speaker: AbbVie, Novartis, UCB, Eli Lily, Incyte, SUN, Amgen
Advisory Board: Janssen, Castle Bioscience, AbbVie, Novartis, UCB, Eli Lily, Acrutis, Incyte, SUN, Amgen
|Name of Editor/Scientific Reviewer||Reported Financial Relationship|
|Peter Lio, MD||
Speaker: Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, Incyte, L'Oreal
Advisory Board: Almirall, ASLAN Pharmaceuticals, Dermavant, Regeneron/Sanofi, Genzyme, Pfizer, LEO Pharmaceuticals, AbbVie, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, KPAway, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, YobeeCare, Burt's Bees, My-Or Diagnostics, Kimberly-Clark
Research: AOBiome, Regeneron/Sanofi Genzyme, and AbbVie
Patent Holder: Theraplex AIM (Patent Pending)
Stockholder: Micreos, YobeeCare, and Altus Labs, KPAway, LearnSkin
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Content Manager||Reported Financial Relationship|
|Maria Mas, Planner||No relationships with a commercial interest to disclose|
|Planners at Your CE Source||No relationships with a commercial interest to disclose|
All other faculty, planner and/or content managers have nothing to disclose nor do they have any vested interests or affiliations. All conflicts of interest have been resolved.